[Skip to Content]
[Skip to Content Landing]
Article
August 1989

MK-927: A Topically Effective Carbonic Anhydrase Inhibitor in Patients

Arch Ophthalmol. 1989;107(8):1143-1146. doi:10.1001/archopht.1989.01070020209026
Abstract

• The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients. Three drops of 2% MK-927 was administered in a two-center, double-masked, randomized, placebocontrolled, two-period crossover study in 25 patients with bilateral primary open angle glaucoma or ocular hypertension. At 4.5 hours after the dose, MK-927-treated eyes demonstrated a peak mean change of −7.7 mm Hg from a mean intraocular pressure of 27.8 mm Hg immediately before the dose; this compares with a change of −3.9 mm Hg from a mean intraocular pressure of 28.2 mm Hg when the same eyes were treated with placebo. The peak mean percent change in intraocular pressure in eyes treated with MK-927 was −26.7% at 6 hours after the dose compared with a change of −13.7% after treatment with placebo. No contralateral effect on intraocular pressure due to MK-927 was observed.

×